A blood-based signature of five microRNAs demonstrated the ability to predict OS of patients with lung cancer receiving immunotherapy and stratify them for treatment, according to a study published in npj Precision Oncology.
Researchers reported that because the signature appears to work from a single timepoint before treatment, it differs from classical circulating tumor DNA-based assays, where blood at baseline is typically dynamically compared with follow-up samples.
“Importantly, the signature does not require any prior tumor tissue analysis and could be used in an ‘off-the-shelf’